Diabetic Retinopathy - Pipeline Review, H1 2020

May 2020 | 324 pages | ID: D8A40E0402EEN
Global Markets Direct

Abstracts

Diabetic Retinopathy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2020, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders)

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020 The guide covers therapeutics under Development by Companies/Universities/Institutes,

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Diabetic Retinopathy - Overview
Diabetic Retinopathy - Therapeutics Development
Diabetic Retinopathy - Therapeutics Assessment
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Diabetic Retinopathy - Drug Profiles
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Retinopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Diabetic Retinopathy - Pipeline by 3SBio Inc, H1 2020
Diabetic Retinopathy - Pipeline by A6 Pharmaceuticals LLC, H1 2020
Diabetic Retinopathy - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
Diabetic Retinopathy - Pipeline by Adverum Biotechnologies Inc, H1 2020
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Diabetic Retinopathy - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
Diabetic Retinopathy - Pipeline by Akaal Pharma Pty Ltd, H1 2020
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2020
Diabetic Retinopathy - Pipeline by Apexian Pharmaceuticals Inc, H1 2020
Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H1 2020
Diabetic Retinopathy - Pipeline by AptaBio Therapeutics Inc, H1 2020
Diabetic Retinopathy - Pipeline by Aptamer Sciences Inc, H1 2020
Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H1 2020
Diabetic Retinopathy - Pipeline by Ascentage Pharma Group International, H1 2020
Diabetic Retinopathy - Pipeline by BetaStem Therapeutics Inc, H1 2020
Diabetic Retinopathy - Pipeline by Bio-Thera Solutions Ltd, H1 2020
Diabetic Retinopathy - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..1), H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..2), H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..3), H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..4), H1 2020
Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..5), H1 2020
Diabetic Retinopathy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Retinopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
A6 Pharmaceuticals LLC
Accuitis Pharmaceuticals Inc
Adverum Biotechnologies Inc
Aerie Pharmaceuticals Inc
Afecta Pharmaceuticals Inc
Akaal Pharma Pty Ltd
Antisense Therapeutics Ltd
Apexian Pharmaceuticals Inc
Applied Therapeutics Inc
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
Boehringer Ingelheim International GmbH
Bonac Corp
CCRP Therapeutics GmbH
Cell Care Therapeutics Inc
Charlesson LLC
Clayton Biotechnologies Inc
Coherus BioSciences Inc
Curacle Co Ltd
Dimerix Ltd
Elasmogen Ltd
Emerald Bioscience Inc
Ennovabio
Epigen Biosciences Inc
Everglades Biopharma LLC
Excitant Therapeutics LLC
EyePoint Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Formycon AG
Generium
Glycadia Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hana Pharm Co Ltd
HanAll Biopharma Co Ltd
Hengenix Biotech Inc
iVeena Delivery Systems Inc
Kato Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kubota Vision Inc
Kuur Therapeutics Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
Mirae Cell Bio Co Ltd
Mirrx Therapeutics A/S
Nanoscope Therapeutics Inc
NeuMedics Inc
Neurodegeneration Therapeutics Inc
NGM Biopharmaceuticals Inc
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
OcuNexus Therapeutics Inc
OliPass Corporation
Opera Therapeutics
Oxurion NV
Palatin Technologies Inc
Panoptes Pharma GesmbH
Phanes Therapeutics Inc
PharmAbcine Inc
Profarma
Protheragen Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Retinset SL
Retrotope Inc
Reven Pharmaceuticals Inc
Rezolute Inc
Serodus ASA
Singh Biotechnology LLC
SiNOPSEE Therapeutics Pte Ltd
Skyran Biologics Inc
Stealth BioTherapeutics Corp
SunBio Inc
Sylentis SAU
Teraclon IDF SL
Topadur Pharma AG
Translatum Medicus Inc
Valitor Inc
VESSL Therapeutics Ltd
Wntgen LLC
Xbrane Biopharma AB
YD Life Science Co
Zih Yuan Tang Biotechnology Co Ltd